Phosphate Lowering in CKD Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 15, 2014

Primary Completion Date

June 28, 2019

Study Completion Date

December 20, 2019

Conditions
Chronic Kidney DiseaseCardiovascular Disease
Interventions
DRUG

Lanthanum carbonate

Non-calcium containing phosphorus binder

DRUG

placebo

Table identical to lanthanum carbonate but with no active ingredient

DRUG

Ascorbic Acid

Intravenous administration during measurement of flow mediated dilation.

DRUG

Nitroglycerin

Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.

PROCEDURE

Flow-mediated dilation measurement

Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.

PROCEDURE

Aortic pulse-wave velocity

Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.

PROCEDURE

Endothelial cell collection

Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.

Trial Locations (1)

80045

Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT02209636 - Phosphate Lowering in CKD Trial | Biotech Hunter | Biotech Hunter